Biologics by McKesson

01/30/2026

Did you know that thyroid cancer is the most common kind of endocrine cancer? While it often develops silently, it's usually treatable if found early. Genetic factors and radiation may increase the risk of thyroid cancer.

Thyroid cancer starts in the thyroid—a small, butterfly-shaped gland in the neck. This gland produces hormones that control metabolism, heart rate, and body temperature. When thyroid cells mutate, they grow uncontrollably and form tumors.

— About 44,000 new cases of thyroid cancer are expected in the U.S. in 2025, making up 2.2% of all new cancer cases.

— Women are three times more likely to develop thyroid cancer than men.

— There may not be any symptoms early on. Later signs may include a neck lump, hoarseness, difficulty swallowing, or neck pain.

Better awareness ensures that patients speak with their doctors earlier if they notice any symptoms. It also supports ongoing research for better treatments. All of this can help save lives.

At Biologics, we stand with patients, caregivers, and healthcare providers who are helping to make progress in the fight against thyroid cancer.

🔗 Learn more: https://www.cancer.org/cancer/types/thyroid-cancer.html

01/28/2026

The work we do at Biologics is about more than just making sure patients get their medications. It's also about delivering high-touch support to the people who need it. In other words, it's about offering help throughout the treatment journey.

"I will always remember the first patient I called to schedule a refill," says Mary Falco Magri, Client Management Specialist. "That one phone call creates a huge impact to the patient’s life, knowing they are receiving their therapy on time."

Thank you for living our values and being there for our patients, Mary! We're glad to have you on the team.

Join us: https://biologics.mckesson.com/careers/

01/26/2026

Today, we’d like to shine a light on Molybdenum Cofactor Deficiency Type A (MoCD-A). This rare genetic disorder affects newborns, and it may go undetected until symptoms start to progress. This can happen very quickly.

MoCD-A is caused by mutations in the MOCS1 gene that make it harder for the body to remove harmful substances. Toxins build up, which can lead to severe brain damage. Babies may have trouble sitting up on their own or learning to speak.

Did you know?

— About 1 in 342,000 to 411,000 babies worldwide are known to have been born with MoCD-A. However, the real number of cases is probably larger since not every child with it gets a diagnosis.

— Babies with MoCD-A look healthy at birth. But within days, they start to develop feeding problems and seizures.

— MoCD-A moves fast and can cause major developmental delays.

Early diagnosis is critical. That means looking out for symptoms like seizures, poor feeding, and strong startle responses. This can be tough because these symptoms are common in other conditions, too. That's why awareness is so important: It helps families, drives research, and leads to life-saving treatment.

At Biologics, we're proud to stand with all of those who are bringing hope to the fight against MoCD-A and other rare diseases.

🔗 Learn more: https://rarediseases.org/rare-diseases/molybdenum-cofactor-deficiency-mocd/

01/23/2026

At the beginning of the year, many insurance plans reset. For providers and patients, this can be a busy time with lots of details to stay on top of. For providers, that often means reverifying coverage to keep care moving without delays.

Biologics helps by reverifying coverage to prevent interruptions in care. We're grateful for our knowledgeable, hardworking staff, who go out of their way to make sure patients get the support they need. Thank you for living our mission of putting patients first! We couldn't do this without you.

01/22/2026

Thanks to our partners, we are able to make sure that patients get the treatments they need. We're proud of the work we do together that puts patients first and leads to better health outcomes.

In this video, John Scott, Head of National Accounts and Specialty Distribution at Agios Pharmaceuticals, talks about the powerful relationship between Agios and Biologics. Together, we help patients with rare diseases stay on their medications and get the help they need.

Watch to learn more.

01/21/2026

For patients with cancer and other chronic conditions, treatment often means dose changes, complex schedules, and high-cost medications. It can be a lot to handle on your own.

At Biologics by McKesson, we make sure patients get the support they need to stay on therapies, reduce costs, and improve outcomes.

Find out more: https://www.linkedin.com/posts/mckesson_at-biologics-by-mckesson-our-proactive-management-activity-7418000853200031745-thEU/

At Biologics by McKesson, our proactive management of medication cycles helps prevent waste, optimizes adherence and delivers critical visibility into therapy regimens to drive down specialty pharmacy costs and improve patient outcomes. Learn more: https://bit.ly/49BLvev

01/19/2026

Being diagnosed with cancer or a rare disease can be scary. The last thing you need is more trouble getting your medication or the support you need.

At Biologics, we make the treatment journey as easy as possible. We're here to help you understand your medications, manage side effects, and answer your questions.

Don't be afraid to reach out and let us know what we can do to help! https://biologics.mckesson.com/contact/

01/15/2026

We had a great time at the Lone Star Oncology Conference on Dec. 6 in Houston, TX! The event was hosted by the local chapter of the Oncology Nursing Society (ONS). It was a good chance to highlight the nurses who work hard every day to support their patients. We got to take part in fun holiday activities like an ugly sweater contest, too!

"The experience was both insightful and energizing," says Azraa Holloway, Regional Practice Liaison. She and Justin Gressman, Director of Sales, got to meet with ONS members throughout the day to talk about how to improve patient care.

Thanks to ONS for hosting this event! We look forward to another year of working together to support nurses.

01/13/2026

Today, we're celebrating 32 years of impact!

From our roots in oncology, we've expanded to support patients facing rare diseases and those seeking breakthroughs in cell and gene therapies. Every step of this journey has been guided by collaboration and compassion because patients have always been – and always will be – at the heart of everything we do.

Here's what that impact looks like:

✔ 200+ oncology and rare disease therapies supported
✔ 26 exclusive therapies delivered with care
✔ 14k+ prescriber partnerships nationwide
✔ 500k+ community resources available through FindHelp
✔ 2 fully redundant dispensing facilities for uninterrupted access
✔ 98% patient satisfaction – because every experience matters

Thank you to our provider and biopharma partners – your partnership helps us bring hope to patients and their families. And to our patients, your strength inspires us every day and reminds us why this journey is only just beginning!

01/12/2026

January 12th is National Pharmacist Day, and we want to take a moment to thank all of the amazing pharmacists we get to work with every day. The care you provide makes a big difference in people's lives.

At our recent holiday party, Stephen Witter, Pharm D, Clinical Oncology Pharmacist, Multispecialty Team, Oncology Pharmacy Services Group, talked about how his work brings meaning to him and hope to his patients. Watch this video for more on what it means to be a pharmacist at Biologics.

Thanks for sharing your story, Steve! And thanks to all of the pharmacists out there who are doing such important work. We're glad to have you on our team.

01/09/2026

The rise of precision oncology is making it possible for us to help more patients. New research is expanding our knowledge of cancer and the best ways to treat it. Together, we can find more ways to apply this research.

In a recent report from McKesson, 200+ experts look at how we can benefit from new approaches to cancer care.

The report features an article by Ela Lourido, VP and General Manager, Specialty Pharmacy Solutions, and Joe DePinto, Head of Cell, Gene, and Advanced Therapies at InspiroGene by McKesson. In it, they look at how treatments like CGT are changing the game. They also discuss how high-touch hub services can help patients get on and stay on their medications.

Read the full article here: https://www.linkedin.com/posts/mckesson_joe-depinto-head-of-cell-gene-and-advanced-activity-7415166683797090305-u6kE

Joe DePinto, head of cell, gene, and advanced therapies, and Ela Lourido, VP and GM, specialty pharmacy solutions at McKesson, share how integrating logistics, specialty pharmacy, patient support and practice solutions enables biopharma and community oncology to make precision medicine an accessible...

01/07/2026

Have you looked into changes to Medicare Part D this year? There are some important things to keep in mind for 2026:

✔️ The out-of-pocket maximum (OOP) has increased by $100—from $2,000 to $2,100.

✔️ Medicare is now using Maximum Fair Prices (MFPs) with ten high-cost, widely used drugs. These changes will likely reduce patient OOP costs by 38% to 79%, depending on the drug.

✔️ Imbruvica is the only drug Biologics dispenses that will be affected by these MFP changes.

Still have questions about how to afford your medications? Find out more here: https://biologics.mckesson.com/patients/financial-assistance/